Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2013

View Archived Issues

Boehringer Ingelheim patents new CCR2 receptor antagonists

Scientists elucidate factors necessary for platelet killing of P. falciparum

Takeda provides overview of activities from April-December 2012

Immune responses analyzed in infants administered an enterovirus vaccine

Bristol-Myers Squibb patents new Y4 receptor agonists

New PI3Kgamma and delta inhibitors disclosed by Infinity Pharmaceuticals and Intellikine

Scientists at Theracrine patent novel agents for cancer

Laboratorios del Dr. Esteve synthesizes novel sigma1-receptor ligands

Nanjing Molecular Research divulges new agents for HCV infection

GlaxoSmithKline: fourth quarter 2012 in review

First-in-human results of LNP-encapsulated siRNA therapy show promise in cancer patients

Albany Molecular Research out-licenses tubulin inhibitor

Champions Oncology receives on-time payment under Teva technology collaboration

TG Therapeutics opens expansion cohorts in trial of ublituximab

Catabasis Pharmaceuticals reports phase I data for CAT-1004

Synageva BioPharma begins phase III ARISE trial

UCB and Amgen decide not to pursue romosozumab program in fracture healing

Galenica provides update on regulatory processes for PA-21

Pediatric indication of Ixiaro approved in Europe

French group synthesizes new imino-sugar derivatives

Pfizer presents new GPR119 receptor agonists

Merck KGaA synthesizes novel FSH receptor agonists

Revlimid approved in China, gets priority review for new indication in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...